Investigational Device · Provisional Patent Filed

Muscle Regeneration,
Delivered at the Point of Care

Myorenova is developing InjectaGel — a field-deployable injectable scaffold system designed to accelerate recovery from acute skeletal muscle injuries.

3.6M+
Muscle strain injuries per year in the US
96.1%
Cell viability in vitro (ISO 10993)
<2 min
Field deployment time
The Problem

Muscle injuries have no repair solution

Acute skeletal muscle strains — common in military, sports, and occupational settings — affect millions annually. Current standard of care relies on rest, ice, compression, and elevation. There is no FDA-cleared biologic or device that actively promotes muscle tissue regeneration.

The result: prolonged recovery timelines, re-injury risk, and long-term functional deficits — especially in high-demand populations where rapid return to duty or play is critical.

"There is no FDA-cleared injectable treatment designed specifically to repair torn or damaged skeletal muscle at the point of injury."
6–8
Weeks of standard recovery
Even moderate Grade II strains sideline athletes and soldiers for weeks with no active regenerative intervention available.
30%
Re-injury rate within 12 months
Scar tissue formation during passive healing creates biomechanical weak points, significantly elevating re-injury risk.
$7B+
Annual economic burden (US)
Lost productivity, rehabilitation costs, and downstream surgical interventions make muscle injury a major healthcare burden.
0
FDA-cleared point-of-care muscle repair devices
The market gap is clear. No injectable scaffold designed for skeletal muscle regeneration has reached patients.
Our Technology

InjectaGel — A Proprietary Regenerative Scaffold System

InjectaGel is a field-deployable muscle regeneration system combining a proprietary bioactive hydrogel scaffold with a spring-driven dual-barrel autoinjector — engineered for use outside of clinical settings.

Component 01
Proprietary Bioactive Scaffold
A proprietary hydrogel scaffold providing tunable mechanical properties matched to native muscle tissue — supporting cell adhesion, proliferation, and organized regeneration.
Component 02
Body-Activated Gelation
Gelation is engineered to activate at body temperature without external energy sources — no UV light, heat, or power required. Purpose-built for field and sideline deployment.
Component 03
Spring-Driven Autoinjector
A mechanical-only, dual-barrel static-mixer delivery device achieving stoichiometrically precise mixing at ±2.8% accuracy. No electronics, no batteries — operable by non-clinical personnel.
Performance Metric
Verified Result
Status
Cell viability at 24 hours (ISO 10993)
96.1 ± 1.8%
PASS
Cell viability at 7 days
93.4 ± 2.7%
PASS
Scaffold gelation time
2 min 14 sec ± 18 sec
PASS
Young's modulus (target: native muscle range)
24.8 ± 3.4 kPa
PASS
4-week mechanical property retention
76.8 ± 4.9%
PASS
Injector deployment time
1 min 48 sec ± 12 sec
PASS
Sterilization modulus retention (UV screen)
93.1%
PASS
⚠ InjectaGel is an investigational device. It is not FDA cleared or approved, is not CE marked, and is not approved for human use outside authorized investigational frameworks. A provisional patent application has been filed. Proprietary formulation details are protected as trade secrets during the development period.
The Team

Built at Washington University in St. Louis

Myorenova was founded by a multidisciplinary team of biomedical engineers with deep expertise across materials science, mechanical design, and life sciences commercialization.

MA
Myles Anderson
Co-Founder · Development Lead
Led hydrogel formulation development and system architecture. Biomedical Engineering, WashU.
TA
Tyler Atsumi
Co-Founder · Business & IP
Responsible for corporate formation, intellectual property strategy, and commercial development. Biomedical Engineering, WashU.
DB
Dominic Begora
Co-Founder · Injector Engineering
Led mechanical design and verification of the spring-driven dual-barrel autoinjector system. Biomedical Engineering, WashU.
Advisors & Partners
Sling Health Medtech Accelerator
Skandalaris Center WashU Entrepreneurship
Contact

Partner with Myorenova

We are actively seeking pre-seed investment, research partnerships, and clinical collaborators. Reach out to learn more about InjectaGel and our development roadmap.